Resverlogix EBIT

The latest EBIT for RVX.TO is $-4M as of June 2026. That compares with $-7.9M in the prior-year period — up 49.5% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Resverlogix's historical trend and sector peers before judging valuation or financial health.

Over the past year, RVX.TO's EBIT moved from $-7.9M to $-4M — a 49.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Resverlogix's operating scale or balance-sheet position.

Against Healthcare companies, RVX.TO currently prints $-4M for EBIT, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Resverlogix's growth, margins, and balance sheet.

A EBIT figure of $-4M for RVX.TO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting RVX.TO's EBIT ($-4M), review year-over-year change from $-7.9M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.